Krajina: Írsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
MIRTAZAPINE
Glob Limited
30 Milligram
Film Coated Tablet
2011-09-30
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mirtazapine Glob 30 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 30 mg film coated tablet contains mirtazapine 30 mg. Each Mirtazapine Glob 30 mg film-coated tablet contains 204 mg lactose (as monohydrate). For a full list of excipients, see Section 6.1 3 PHARMACEUTICAL FORM Film coated tablet Mirtazapine 30 mg tablets are Reddish Brown, biconvex, capsule shaped, film coated tablets with a score line in between 0 and 9 debossed on one side and ‘A’ on the other side. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of episodes of major depression. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults The effective daily dose is usually between 15 and 45 mg; the starting dose is 15 or 30 mg. MIRTAZAPINE BEGINS TO EXERT ITS EFFECT IN GENERAL AFTER 1-2 WEEKS OF TREATMENT. TREATMENT WITH AN ADEQUATE DOSE SHOULD RESULT IN A POSITIVE RESPONSE WITHIN 2-4 WEEKS. WITH AN INSUFFICIENT RESPONSE, THE DOSE CAN BE INCREASED UP TO THE MAXIMUM DOSE. IF THERE IS NO RESPONSE WITHIN A FURTHER 2-4 WEEKS, THEN TREATMENT SHOULD BE STOPPED. Elderly The recommended dose is the same as that for adults. In elderly patients an increase in dosing should be done under close supervision to elicit a satisfactory and safe response. Children and adolescents under the age of 18 years Mirtazapine should not be used in children and adolescents under the age of 18 years as efficacy was not demonstrated in two short-term clinical trials (see section 5.1) and because of safety concerns (see sections 4.4, 4.8 and 5.1). Renal impairment The clearance of mirtazapine may be decreased in patients with moderate to severe renal impairment (creatinine cleara Prečítajte si celý dokument